drugset / Trial / NCT00621322
Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy Adults
RandomizedParallel-groupTriple-blindPrevention
Summary
This observer blind study will assess the safety and immunogenicity of different formulations of GSK Biologicals' 692342 tuberculosis vaccine in healthy adults aged 18 to 45 years with a positive PPD skin test. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Timeline
- Start
- 2008-04-03
- Primary completion
- 2009-04-03
- Completion
- 2009-04-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 1 | Vaccine | — | Intramuscular |
| Subject | GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 2 | Vaccine | — | Intramuscular |
| Subject | GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 3 | Vaccine | — | Intramuscular |
| Subject | GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 | Vaccine | — | Intramuscular |